{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:46:49Z","timestamp":1761821209368},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs in R & D"],"published-print":{"date-parts":[[2005]]},"DOI":"10.2165\/00126839-200506050-00001","type":"journal-article","created":{"date-parts":[[2006,1,20]],"date-time":"2006-01-20T05:38:09Z","timestamp":1137735489000},"page":"253-260","source":"Crossref","is-referenced-by-count":16,"title":["Eslicarbazepine Acetate (BIA 2-093)"],"prefix":"10.1007","volume":"6","author":[{"given":"Carlos","family":"Fontes-Ribeiro","sequence":"first","affiliation":[]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Amilcar","family":"Falc??o","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Neta","sequence":"additional","affiliation":[]},{"given":"Ricardo","family":"Lima","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Tice","family":"Macedo","sequence":"additional","affiliation":[]},{"given":"Patricio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"R1-1","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","volume":"42","author":"Benes","year":"1999","journal-title":"J Med Chem"},{"key":"R2-1","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1528-1157.2001.43600.x","volume":"42","author":"Bonifacio","year":"2001","journal-title":"Epilepsia"},{"issue":"5","key":"R4-1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/00126839-200304050-00001","volume":"4","author":"Almeida","year":"2003","journal-title":"Drugs RD"},{"key":"R5-1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0091270004267591","volume":"44","author":"Almeida","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"R6-1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2165\/00126839-200506040-00002","volume":"6","author":"Maia","year":"2005","journal-title":"Drugs RD"},{"issue":"6","key":"R10-1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J Pharmacokinet Biopharm"}],"container-title":["Drugs in R & D"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T10:13:40Z","timestamp":1553163220000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/00126839-200506050-00001"}},"subtitle":["Relative Bioavailability and Bioequivalence of 50 mg\/mL Oral Suspension and 200mg and 800mg Tablet Formulations"],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":6,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.2165\/00126839-200506050-00001","relation":{},"ISSN":["1174-5886"],"issn-type":[{"value":"1174-5886","type":"print"}],"subject":[],"published":{"date-parts":[[2005]]}}}